Background
Methods
Study design and participants
Clinical assessments
Laboratory analysis
Gene | Forward primer | Reverse primer |
---|---|---|
Resistin | 5′-TCT AGC AAG ACC CTG TGC-3′ | 5′-TGC TTA TTG CCC TAA ATA TTA G-3′ |
Adiponectin | 5′-AGT CTG TGG TTC TGA TTC C-3′ | 5′-TTG AGT CGT GGT TTC CTG-3′ |
Leptin | 5′-TTT CAC ACA CGC AGT CAG-3′ | 5′-CCA TCT TGG ATA AGG TCA GG-3′ |
IL-6 | 5′-CTG GAT TCA ATG AGG AGA CTT G-3′ | 5′-CTC ACT ACT CTC AAA TCT GTT CTG-3′ |
Visfatin | 5′-CGG TTC TGG TGG AGG TTT GC-3′ | 5′-CCT GCT GGC GTC CTA TGT AAA G-3′ |
TNF-α | 5′-GGG AGC CTT TGG TTC TGG-3′ | 5′-AGG AAG TCT GGA AAC ATC TGG-3′ |
Apelin | 5′-GCT CTC ACC TCG CAC CTG-3′ | 5′-GAT GGA CTG GAC GGA TTC TTG-3′ |
CYCA | 5′-ATC CTA GAG GTG GCG GAT TT-3′ | 5′-CAC TCA GGT CTG AGC CAC AA-3′ |
Statistical analysis
Results
Study group characteristics
Controls (n = 14) | Obesity (n = 27) | Obesity + T2DM (n = 14) | |
---|---|---|---|
Age (years) | 59.6 ± 12.1 | 61.6 ± 9.6 | 62.9 ± 11.2 |
Height (cm) | 172 ± 7 | 171 ± 5 | 172 ± 5 |
Weight (kg) | 71.0 ± 7.8 | 86.6 ± 10.9† | 90.3 ± 8.2† |
Hip circumference (cm) | 96.5 ± 6.2 | 109.0 ± 8.3† | 106.9 ± 7.5† |
Waist circumference (cm) | 91.6 ± 6.3 | 106.0 ± 8.5† | 109.5 ± 8.0† |
Waist-to-hip ratio | 0.95 ± 0.06 | 0.97 ± 0.04 | 1.03 ± 0.06†,‡ |
BMI (kg/m2) | 24.0 ± 1.9 | 29.4 ± 3.0† | 30.6 ± 2.7† |
SBP (mmHg) | 124 ± 13 | 128 ± 13 | 132 ± 13 |
DBP (mmHg) | 72 ± 6 | 75 ± 7 | 74 ± 6 |
Disease status | |||
Hypertension, n (%) | 10 (71%) | 22 (81%) | 12 (86%) |
Dyslipidemia, n (%) | 7 (50%) | 17 (63%) | 7 (50%) |
NYHA [I/II/III/IV] | 1/12/1/0 | 3/24/0/0 | 2/10/2/0 |
CCS [I/II/III/IV] | 1/11/2/0 | 2/23/2/0 | 2/9/3/0 |
HFrEF, n (%) | 11 (79%) | 12 (44%) | 6 (43%) |
HFpEF, n (%) | 2 (14%) | 14 (52%) | 7 (50%) |
Biochemistry | |||
Glucose (mg/dL) | 80.5 ± 6.1 | 86.7 ± 7.1 | 104.1 ± 24.4†,‡ |
Insulin (mU/L) | 5.34 ± 2.35 | 8.94 ± 4.75† | 8.44 ± 3.34† |
HOMA2-IR | 0.77 ± 0.33 | 1.30 ± 0.70† | 1.31 ± 0.57† |
HbA1c (%) | 5.77 ± 0.40 | 5.66 ± 0.48 | 7.61 ± 1.39†,‡ |
Triglycerides (mg/dL) | 121 ± 72 | 146 ± 66 | 226 ± 197† |
Total cholesterol (mg/dL) | 175 ± 43 | 169 ± 51 | 155 ± 47 |
HDL-cholesterol (mg/dL) | 37.6 ± 9.3 | 35.2 ± 6.3 | 34.1 ± 11.5 |
LDL-cholesterol (mg/dL) | 114 ± 39 | 106 ± 45 | 83 ± 38 |
Drugs | |||
Beta-blockers, n (%) | 12 (86%) | 24 (89%) | 12 (86%) |
Angiotensin-converting-enzyme inhibitor, n (%) | 13 (93%) | 23 (85%) | 13 (93%) |
Statins, n (%) | 10 (71%) | 25 (93%) | 12 (86%) |
Metformin, n (%) | 0 | 0 | 7 (50%) |
Sulfonyloureas, n (%) | 0 | 0 | 7 (50%) |
Insulin, n (%) | 0 | 0 | 5 (36%) |
Echocardiographic examination of heart structure and function
Controls | Obesity | Obesity + T2DM | |
---|---|---|---|
EF (%) | 47.7 ± 9.0 | 51.7 ± 9.7 | 53.4 ± 10.1 |
FS (%) | 26.5 ± 7.7 | 33.2 ± 8.8 | 28.9 ± 7.1 |
TAPSE (mm) | 25.9 ± 5.7 | 26.1 ± 4.1 | 24.0 ± 4.6 |
E/A | 0.9 ± 0.3 | 0.8 ± 0.3 | 0.9 ± 0.4 |
DT (ms) | 255.8 ± 86.9 | 227.6 ± 48.1 | 234.2 ± 64.7 |
IVRT (ms) | 111.8 ± 21.2 | 107.9 ± 17.8 | 99.0 ± 19.6 |
E’ (cm/s) | 8.0 ± 2.5 | 7.7 ± 1.7 | 7.0 ± 2.1 |
A’ (cm/s) | 8.3 ± 1.9 | 8.7 ± 2.1 | 8.9 ± 1.5 |
DT’ (ms) | 167.8 ± 63.3 | 165.5 ± 48.9 | 162.4 ± 57.3 |
E’/A’ | 1.1 ± 0.5 | 0.9 ± 0.3 | 0.8 ± 0.3 |
RVAC (mL) | 43.9 ± 15.7 | 40.6 ± 9.5 | 39.8 ± 10.2 |
EATt (mm) | 9.9 ± 2.2 | 12.1 ± 3.6 | 11.7 ± 2.9 |
LA (cm) | 4.0 ± 0.4 | 4.1 ± 0.4 | 4.4 ± 0.5† |
LVdD (cm) | 5.4 ± 0.7 | 5.5 ± 0.5 | 5.4 ± 0.5 |
LVsD (cm) | 3.9 ± 0.8 | 3.6 ± 0.6 | 3.9 ± 0.5 |
RVdD (cm) | 2.4 ± 0.4 | 2.7 ± 0.4† | 2.6 ± 0.4 |
IVSD (cm) | 1.1 ± 0.2 | 1.1 ± 0.2 | 1.2 ± 0.2 |
PWTd (cm) | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.2 |
RWT | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
LVM (g) | 226.8 ± 61.5 | 251.8 ± 58.6 | 260.0 ± 62.7 |
LVMi (g/m2.7) | 52.9 ± 14.5 | 58.4 ± 11.8 | 59.9 ± 12.6 |
Plasma adipokine concentration
Expression of adipokines in SAT and EAT depots
Comparison of adipokine mRNA and protein expression in SAT and EAT depots
Association between tissue expression and plasma concentration of adipokines and heart structure and function
β
|
p
| |
---|---|---|
Systolic heart function | ||
EF | ||
Apelin SAT mRNA | − 0.29 ± 0.13 | 0.036 |
TNF-α EAT mRNA | − 0.36 ± 0.13 | 0.010 |
IL-6 SAT protein | 0.38 ± 0.16 | 0.025 |
Leptin SAT protein | 0.37 ± 0.16 | 0.033 |
TAPSE | ||
IL-6 plasma | − 0.34 ± 0.14 | 0.015 |
Diastolic heart function | ||
E/A | ||
Apelin plasma | 0.40 ± 0.12 | 0.001 |
Resistin plasma | − 0.30 ± 0.12 | 0.017 |
Resistin SAT mRNA | − 0.36 ± 0.12 | 0.005 |
Leptin plasma | − 0.28 ± 0.13 | 0.033 |
DT | ||
Resistin plasma | 0.38 ± 0.13 | 0.005 |
Adiponectin plasma | 0.36 ± 0.13 | 0.007 |
Adiponectin SAT mRNA | 0.31 ± 0.13 | 0.025 |
Adiponectin SAT protein | 0.52 ± 0.15 | 0.002 |
Apelin SAT mRNA | 0.34 ± 0.13 | 0.012 |
E′ | ||
IL-6 plasma | − 0.28 ± 0.13 | 0.030 |
A′ | ||
Leptin plasma | 0.34 ± 0.16 | 0.041 |
Leptin EAT protein | 0.49 ± 0.15 | 0.003 |
E′/A′ | ||
IL-6 plasma | − 0.34 ± 0.13 | 0.014 |
IL-6 EAT protein | − 0.37 ± 0.17 | 0.033 |
DT′ | ||
Leptin EAT mRNA | 0.44 ± 0.13 | 0.002 |
Resistin SAT mRNA | 0.35 ± 0.13 | 0.008 |
Heart structure | ||
EATt | ||
Apelin SAT mRNA | 0.35 ± 0.14 | 0.014 |
PWTd | ||
Visfatin plasma | 0.46 ± 0.13 | 0.001 |
Adiponectin plasma | − 0.37 ± 0.13 | 0.005 |
Leptin EAT protein | − 0.38 ± 0.16 | 0.021 |
RVdD | ||
Resistin plasma | 0.39 ± 0.12 | 0.002 |
TNF-α SAT mRNA | 0.27 ± 0.13 | 0.036 |
LA | ||
Visfatin EAT protein | − 0.38 ± 0.15 | 0.017 |
IVSD | ||
Leptin EAT mRNA | 0.28 ± 0.13 | 0.041 |
LVM | ||
TNF-α SAT mRNA | 0.35 ± 0.13 | 0.011 |